Argos Therapeutics, Inc. (ARGS) Posts Q2 Loss of 61c/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Argos Therapeutics, Inc. (ARGS) Posts Q2 Loss of 61c/Share

Argos Therapeutics Reports Second Quarter 2014 Financial Results and Operational Highlights

August 13, 2014 4:05 PM EDT

DURHAM, N.C., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq: ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform, today reported financial results for the second quarter ended June 30, 2014, and provided an update on the Company's clinical programs.

"We continue to be pleased with the progress we are making in our ADAPT phase 3 trial of AGS-003 in metastatic renal cell carcinoma (mRCC), as we now have collected tumors for screening for eligibility... More